• Welcome to FZATA
  • R&D Pipeline

    R&D Pipeline

    Clostridium Difficile infection (CDI) Field

    1. FZ003: Humanized tetrospecific neutralizing antibody against CDI. FZ003 is entering GMP manufacture
    2. FZ002:  Probiotic yeast delivered tetrospecific antibody as prophylactic and therapeutic for CDI. FZ002 demonstrated excellent efficacy in CDI animal model and entering stage of formulation optimization  

    Inflammatory Bowel Disease Field

    Leads identification